Search research articles
Contact Us
Filters
Showing results (51-60 of 57) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 57 results.
Cancer
|
December 22, 2005
The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera
Ayalew Tefferi, Terra L Lasho, Susan M Schwager, et al.
Cancer
|
July 11, 2006
Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial
Alvaro Moreno-Aspitia, Gerardo Colon-Otero, Antje Hoering, et al.
Blood
|
July 31, 2004
FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia
Animesh Pardanani, Stephanie R Brockman, Sarah F Paternoster, et al.
Cancer
|
April 19, 2007
Clinical correlates of JAK2V617F allele burden in essential thrombocythemia
Jaya Kittur, Ryan A Knudson, Terra L Lasho, et al.
Blood
|
January 9, 2003
A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia
Ruben A Mesa, David P Steensma, Animesh Pardanani, et al.
Blood
|
July 5, 2003
CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy
Animesh Pardanani, Rhett P Ketterling, Stephanie R Brockman, et al.
Blood
|
October 24, 2002
Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study
Catherine Metayer, Rochelle E Curtis, Julie Vose, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 57) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 57 results.
Cancer
|
December 22, 2005
The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera
Ayalew Tefferi, Terra L Lasho, Susan M Schwager, et al.
Cancer
|
July 11, 2006
Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial
Alvaro Moreno-Aspitia, Gerardo Colon-Otero, Antje Hoering, et al.
Blood
|
July 31, 2004
FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia
Animesh Pardanani, Stephanie R Brockman, Sarah F Paternoster, et al.
Cancer
|
April 19, 2007
Clinical correlates of JAK2V617F allele burden in essential thrombocythemia
Jaya Kittur, Ryan A Knudson, Terra L Lasho, et al.
Blood
|
January 9, 2003
A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia
Ruben A Mesa, David P Steensma, Animesh Pardanani, et al.
Blood
|
July 5, 2003
CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy
Animesh Pardanani, Rhett P Ketterling, Stephanie R Brockman, et al.
Blood
|
October 24, 2002
Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study
Catherine Metayer, Rochelle E Curtis, Julie Vose, et al.
Page
of 6